Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL634874 | 0.75 | TAAR1 (0.38) | SMN1; SMN2ALDH1A1NPC1EPHX1RAB9A | |
| SCHEMBL11134470 | 0.75 | TAAR1 (0.38) | SMN1; SMN2ALDH1A1NPC1EPHX1RAB9A | |
| SCHEMBL153483 | 0.75 | TAAR1 (0.38) | SMN1; SMN2ALDH1A1NPC1EPHX1RAB9A | |
| SCHEMBL28568464 | 0.75 | — | — | |
| SCHEMBL21319042 | 0.73 | ALDH1A1 (0.33) | ALOX15ALDH1A1NPC1RAB9A | |
| SCHEMBL10917130 | 0.72 | ALDH1A1 (0.42) | CXCR3SMN1; SMN2ALOX15ALDH1A1NPC1 | |
| SCHEMBL4842355 | 0.72 | ALDH1A1 (0.38) | CXCR3SMN1; SMN2ALOX15ALDH1A1NPC1 | |
| SCHEMBL850818 | 0.71 | KDM1A (0.33) | — | |
| SCHEMBL2513477 | 0.71 | ALDH1A1 (0.52) | CXCR3SMN1; SMN2ALOX15ALDH1A1NPC1 | |
| SCHEMBL7593007 | 0.71 | KDM1A (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 310 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210213700-A1 | PACKAGING FOR ADHESIVE COMPOSITIONS | H.B. FULLER MEDICAL ADHESIVE TECHNOLOGIES, LLC. | 2021-07-15 | — | — | US | claimed |
| WO-2018148057-A1 | PACKAGING FOR ADHESIVE COMPOSITIONS, METHOD FOR STERILIZING | ADHEZION BIOMEDICAL, LLC (US) | 2018-08-16 | — | — | WO | claimed |
| US-20180222618-A1 | PACKAGING FOR ADHESIVE COMPOSITIONS | H.B. FULLER MEDICAL ADHESIVE TECHNOLOGIES, LLC. | 2018-08-09 | — | — | US | claimed |
| WO-2012059403-A1 | COSMETIC COMPOSITION AND PROCESS FOR CURLING KERATIN FIBRES | L'OREAL (FR) | 2012-05-10 | — | — | WO | claimed |
| EP-1372844-B1 | HIGH ACTIVITY METAL CARBENE METATHESIS CATALYSTS GENERATED USING A THERMALLY ACTIVATED N-HETEROCYCLIC CARBENE PRECURSOR | CALIFORNIA INST OF TECHN (US) | 2011-01-05 | — | — | EP | claimed |
| EP-1372844-A4 | HIGH ACTIVITY METAL CARBENE METATHESIS CATALYSTS GENERATED USING A THERMALLY ACTIVATED N-HETEROCYCLIC CARBENE PRECURSOR | CALIFORNIA INST OF TECHN (US) | 2005-10-12 | — | — | EP | claimed |
| US-6838489-B2 | High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor | CYMETECH, LLC (US) | 2005-01-04 | — | — | US | claimed |
| EP-1372844-A1 | HIGH ACTIVITY METAL CARBENE METATHESIS CATALYSTS GENERATED USING A THERMALLY ACTIVATED N-HETEROCYCLIC CARBENE PRECURSOR | California Institute of Technology (US) | 2004-01-02 | — | — | EP | claimed |
| WO-2003097562-A2 | HIGH ACTIVITY METAL CARBENE METATHESIS CATALYSTS GENERATED USING A THERMALLY ACTIVATED N-HETEROCYCLIC CARBENE PRECURSOR | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2003-11-27 | — | — | WO | claimed |
| US-20030144437-A1 | High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor | STERLING JA, L.C. | 2003-07-31 | — | — | US | claimed |
| US-5468803-A | Medical implement, polymer composition, and optical material | NIPPON ZEON CO. LTD. (JP) | 1995-11-21 | — | — | US | claimed |
| EP-0426142-B1 | Method of making ring-opened polynorbornene polymers using pot life extending agents | NIPPON ZEON CO (JP) | 1995-09-20 | — | — | EP | claimed |
| US-5439992-A | Continuous process for making melt-processable optical grade ring-opened polycyclic (co)polymers in a single-stage multi-zoned reactor | THE B. F. GOODRICH COMPANY (US) | 1995-08-08 | — | — | US | claimed |
| EP-0454059-B1 | Composite molded articles | NIPPON ZEON CO (JP) | 1995-05-17 | — | — | EP | claimed |
| US-5204427-A | Without prolonging smoke time; molybdenum metathesis catalyst and cocatalyst; bicyclic polyunsaturated extender | NIPPON ZEON CO., LTD. (JP) | 1993-04-20 | — | — | US | claimed |
| US-5160772-A | COMPOSITE MOLDED ARTICLES | NIPPON ZEON CO., LTD. (JP) | 1992-11-03 | — | — | US | claimed |
| EP-0488135-A2 | Bulk polymerizable reaction solutions | NIPPON ZEON CO., LTD. (JP) | 1992-06-03 | — | — | EP | claimed |
| EP-0454059-A2 | Composite molded articles | NIPPON ZEON KABUSHIKI KAISHA (JP) | 1991-10-30 | — | — | EP | claimed |
| EP-0426142-A2 | Method of making ring-opened polynorbornene polymers using pot life extending agents | NIPPON ZEON CO., LTD. (JP) | 1991-05-08 | — | — | EP | claimed |
| US-4178424-A | USED FOR AUTOMOTIVE PARTS | THE BF GOODRICH COMPANY (US) | 1979-12-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144437-A1 | High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor | NQO1, NIT2, ALOX5 | CXCR3 2850/4885SMN1; SMN2 1687/4885ALOX15 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.